Untitled

Abstract

Diabetes mellitus is a metabolic disorder that causes high levels of blood glucose level in that 90% of the diabetic population accounts for type 2 diabetes mellitus it also has secondary complications like Cardiovascular disorder, Renal impairment, and susceptibility to infections. Empagliflozin is a potentially highly selective Sodium-glucose cotransportace-2 (SGLT-2) inhibitor used for the treatment of type 2 diabetes mellitus alone or in combination with the metformin or dipeptidyl peptidase-4 (DPP-4) inhibitors. The literature entitles the various analytical techniques like UV spectroscopy, High Performance Liquid Chromatography, High Performance Thin Layer Chromatography, Liquid Chromatography-Mass spectrometry. In this literature, we reviewed the various analytical, stability studies, impurity profiling and bio-analytical methods used for the estimation of Empagliflozin. This review gives the concise and collective information about the analytical validating parameters like Limit of detection (LOD), Limit of Quantification (LOQ), Standard Curve, Accuracy & Precision for the analysis of Empagliflozin alone or in combination with the Linagliptin or Metformin. This review helps to carryout further analytical studies on the mentioned drugs. INTRODUCTION: Diabetes mellitus is a chronic metabolic disorder in which the ability of the pancreatic cells to produce or respond to the insulin hormone is decreased. According to WHO, 1.6 million deaths were directly caused and 2.2 million deaths caused due to contraindication with other diseases 1, 2. In type 1, diabetes mellitus, the body's immune system destroys the pancreatic cells that produced insulin. Type 2 diabetes mellitus, which is also referred to as non-insulin-dependent diabetes, accounts for more than 90% of patients with diabetes 3, 4 .